Last reviewed · How we verify

Zactran (GAMITHROMYCIN)

FDA-approved active Small molecule Quality 6/100

Gamithromycin (Zactran) is a marketed antibiotic that inhibits bacterial protein synthesis, currently holding a position in the veterinary pharmaceutical market. A key strength of Zactran is its mechanism of action, which effectively targets bacterial protein synthesis, providing a robust therapeutic option. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Generic nameGAMITHROMYCIN
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects